EXCLUSIVE LICENSE AGREEMENT for MSK’s technology EBV/CMV and WT1 specific T-cellsExclusive License Agreement • June 29th, 2015 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), entered into effective as of June 12, 2015 (“Effective Date”), is by and between Memorial Sloan Kettering Cancer Center (“MSK”), a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, and Atara Biotherapeutics, Inc. (“Licensee”), a corporation with offices at 701 Gateway Blvd, Suite 200, South San Francisco, CA 94080. MSK and Licensee are sometimes referred to singly as “Party” and collectively as “Parties.”
